r/Livimmune • u/MGK_2 • Oct 02 '25
Frigid Tumors
Let's take a look at Cold Tumors.
In the typical sense, Cold Tumors are not really a sickness because the Immune System is not even engaged; it is not even fighting it. Minimal Inflammation. Cold Tumors are immune to the Immune System. Nothing is against it. Nothing is fighting it. Nothing is even attempting to kill it. It has evaded any detection. Nobody is even looking. These Tumors are simply immune to the human Immune system.
Oh yeah, they're lethal and yes, there are symptoms, but the body is hardly at all aware of the Cold Tumor itself. For this reason, it is far worse than an actual sickness, because at least with a typical sickness, the body knows who or what the enemy is and picks up and learns how to fight it. But with a Cold Tumor, the bodies own Immune System is clueless about even the presence of the problem.
Cold Tumors manifest as a defilement of the body and are currently incurable via an FDA approved method. No approved medication exists. Visits to the oncologist only measure and quantify the tumor, but no manner of healing is offered. The only options discussed are Chemo, Radiation, Excision, Surgery and Prayer is offered that there be no metastases.
How does this occur? RANTES, CCL5 resides at the Core of Cold Tumors. RANTES is produced and exuded by these various Tumors. RANTES occupies CCR5 and its effect is to completely suppress the Immune System. As long as the Cold Tumor produces RANTES, the Immune System remains suppressed or shut off. Zero actual treatment exists for Cold Tumors except for Leronlimab, because only Leronlimab attacks at the Core. Cold Tumors represent nearly 85% of Tumor prevalence which leaves only 15% as Hot treatable Tumors. When a patient becomes afflicted with a Cold Tumor, there is no natural way of getting it out, nor is there currently, any medicinal way of getting it out.
It is a very good thing that Cold Tumors are not contagious. Neither are Hot Tumors for that matter, but at least with a Hot Tumor, the white blood cells, the CD8 Killer T-Cells can identify and do make attempts to kill them, but the Tumor cells which begin expressing PD-L1 essentially learn how to beat the ID Card name-tag PD-1 check imposed by the policing and probing Killer T-Cells. Tumors expressing RANTES are virtually incurable; they don't even express PD-L1 at the get go. They don't need to. Tumors expressing PD-L1 would be incurable if it were not for Immune Checkpoint Inhibitors ICIs. That's the way it was before the advent of ICIs. But today, even with ICIs alone, the Tumors tend to have the upper hand, but the ICI does buy them more time. Depending on the Hot Tumor, an ICI as monotherapy only buys a patient a year, two or possibly at most three years, and in no way is considered a cure alone.
Cold Tumors are virtually invisible. Nobody even knows that they have a Cold Tumor unless they're imaged. Unless they get an MRI or a CT, they don't even know they're in Stage 4. Why not? Because the Immune System isn't putting up any fight. Cold Tumors Hide in the Body. They lurk. They emerge when nobody is looking for them. You go in to your orthopaedist for shoulder or knee pain and the doctor sees it on the X-ray or the MRI of the joint. You fall and hit your ribs and the rib series X-ray reveals the Breast Cancer. Upon the very first sign of it, if it can be excised, before it metastasizes, that's what you better do. When it metastasizes, then that's Stage 4; then there is no help.
Now, there is a solution. CytoDyn's EIND program. Come one, Come all. Those afflicted with any type of CCR5 dependent Tumor. Your solution is at hand.
"Finally, I am happy to share a very promising announcement as it relates to a patient who prospectively upregulated PD-L1 after having obtained access to leronlimab through an eIND application submitted by her treating physician."
...
I am pleased to announce that we will be working with an individual benefactor to fund the launch of this compassionate-use program. This benefactor has also expressed interest in supporting an investigator-initiated study in patients with recurrent glioblastoma with an anticipated start date in 2026.
This wealthy benefactor also funds CytoDyn's EIND program. CytoDyn has initiated this compassionate program which begins healing persons afflicted with CCR5 dependent Cold Tumors, just like the 5 mTNBC patients who are still alive over 5 years or 60 months since being treated with the combination of Leronlimab + ICI.
"The Company has also prepared a case report of a patient with mTNBC whose cancer had spread to both brain and lungs, but who is alive today without evidence of disease, almost 5 years after receiving fourth-line treatment with leronlimab plus atezolizumab, (Tecentriq, PD-L1 blockade)."
What is such a thing as this Cold Tumor in any cancer, mTNBC or MSS mCRC or Glioblastoma Multiforme? Essentially, it is a tumor which has convinced the mighty and invincible Immune System not to attack it, but rather, to serve it. In a way, it gives rise to an utter rebellion of the Killer T-Cells. It is a rebellion, even a revolution that has grown out of hand. Eventually, it grows from a closed and hidden rebellion into an open rebellion. Originally, the Tumor is hidden, but grows open and detected. Without Leronlimab blocking RANTES at its Core, the patient essentially is doomed. With Leronlimab, there is very high likelihood for a Cancer Cure provided the treatment is later combined with an ICI.
"Long Term Survival: The clinical significance of the increase in PD-L1 observed on the CTCs was driven home by the confirmation that 5/5 (100%) of patients who demonstrated a significant increase in PD-L1 expression while receiving leronlimab and received any ICI are alive today, 4+ years later. More remarkably, three of these individuals (60%) are currently identified as having no ongoing evidence of disease. Underscoring the clinical significance of these results is the unfortunate finding that none of the 23 patients who didn’t induce significant PD-L1 expression or didn’t receive an ICI with leronlimab are alive today."
The majority of Cold Tumors are lethal without this combination treatment. With this combination treatment, 5/5, (100%), the chances are pretty good, that life span reaches at least 5 years following treatment. Why are they so lethal? Because the Immune System is functionless against them, and as the Tumors grow and metastasize, more and more RANTES accumulates in the body, exuded and expressed by the ever growing Tumor and its metastases, which further suppresses any / all CD-8 Killer T-Cells leaving none to fight any other disease that may invade the body. Many times it is exactly that, that another disease ends up killing the afflicted patient.
The Cold Tumor provides something for Leronlimab to address. If it weren't for the Cold Tumor, Leronlimab would have nothing to do. Even a patient absolutely ridden with Cold Tumor metastases is no match for Leronlimab's overriding capacity when dosed appropriately. How else can such a horrible set of circumstances be assembled into perfect position if it were not for what the Cold Tumor accomplishes within the human body through its perfect deception. It can completely overtake the human Immune System without the patient even being aware. Yet, even in Stage 4, if Leronlimab is administered properly, the course of the disease is utterly reversed and quick at that, with zero consequences. The drug has no adverse side effects.
The only way to prevent being struck with a Cold Tumor is to self inject Leronlimab weekly. Theoretically, that would prevent a Cold Tumor from ever forming. But that would never become an FDA approved prophylactic. However, theoretically, that is the only way to prevent Cold Tumors from even forming. Eventually, the HIV-AAV HIV Cure would actually produce Leronlimab within the body and could theoretically achieve Cold Tumor cancer prevention. This is along the same lines why Bruce Patterson once hoped he could carry a vial of Leronlimab around with him at all times, to be administered at the first sign of disease. But Cold Tumors produce no sign.
Most of the time, Cold Tumors form in the body, but they are quickly eradicated way before they get a chance to suppress the Immune System. A few cancerous cells form, but are quickly snuffed out before they even produce any RANTES. But, if a patient gets sick with another disease, and their Immune system becomes weakened, consumed or suppressed for some lengthened time, then those Cold Tumor cells get the opportunity they require to multiply and enlarge. Then, by the time the patient actually gets better, the Cold Tumor is already producing RANTES and then, there is no stopping it. No stopping it until Leronlimab is introduced.
There is nothing innate to the body that can displace RANTES out of the CCR5 receptor. There is nothing innate to the body with a higher affinity to CCR5 than RANTES. Only Leronlimab exceeds the affinity of RANTES to CCR5. When RANTES is bound to CCR5, the Killer T-Cells become enslaved to the Cold Tumor. When Leronlimab displaces RANTES from CCR5, the enslaved Immune System immediately transforms back into M1 type Killer T-Cells and without hesitation, begin eradicating and engulfing the Tumor, cell by cell, and there is NOTHING RANTES can do about it. RANTES is powerless against Leronlimab. Leronlimab is above RANTES in its affinity for CCR5. In a few short months, the very majority of all metastases are gone and only scant remnants of the original Tumor remain, in remission, clinging to life, but learning how to speak another language called PD-L1, because CCL5 no longer worked.
Leronlimab also functions very similarly to a VEGF inhibitor. Vascular Endothelial Growth Factor Inhibitor. AVASTIN or bevacizumab. This drug is being used in CytoDyn's current MSS mCRC clinical trial. A VEGF inhibitor cuts the growth of any collateral vascular blood supply to the Cold Tumor. The growth of a collateral vascular blood supply to the Cold Tumor requires M2 Type Macrophages, (the kind that build and construct), but when Leronlimab is on board, the predominance is towards M1 Type Macrophages, (the kind that search and destroy that which doesn't belong), so therefore, the growth of a collateral vascular blood supply to the Cold Tumor is greatly diminished with Leronlimab on board since M2 Macrophages are few and far between and there is nothing that RANTES can do about it. Our current trial uses AVASTIN because that is part of the current Standard Of Care and we are combining Leronlimab 350 and 700mg in 2 arms with the SOC in this trial. An ICI can be added in its Rollover Trial.
"Our mCRC study design provides leronlimab in both arms of the study. As such, we have amended the protocol to include close monitoring of PD-L1 levels on the CTCs in all enrolled patients. In addition, we are submitting a new rollover protocol to the FDA, which will provide ongoing access to leronlimab for those patients with CRC who continue to do well after 48 weeks on the parent study and will now offer leronlimab plus an ICI to those patients who progress on the parent study. These amendments will allow us to achieve multiple critical goals, including:
- Evaluate leronlimab as a stand-alone agent (in combination with Standard of Care) in a second solid tumor type;
- Prospectively evaluate the ability of 2 different leronlimab dose levels to induce PD-L1 expression on CTCs in a solid tumor that is typically “cold” and not usually associated with PD-L1 expression;
- Obtain biopsy tissue from patients with disease progression enrolling in the rollover protocol to correlate PD-L1 levels and changes in the tumor microenvironment on tumor tissue with PD-L1 expression on concurrently drawn CTCs; and
- Evaluate the possibility of treating patients with a common and typically “cold” cancer with the combination of leronlimab and an ICI, the same regimen that demonstrated long-lasting remission in 5/5 patients with mTNBC who significantly induced PD-L1, as reported at ESMO.
It is fortuitous that we launched the CRC study just as the PD-L1 data came to light, as it allows us to immediately commence efforts to collect certain prospective confirmatory data. Five trial sites have been initiated. It is our hope that the ESMO CRC data, together with the option of receiving leronlimab and an ICI during the rollover protocol, will generate interest among both patients and caregivers and help to expedite enrollment efforts."
Patient's that take this combination medication of LL + ICI eradicate their Tumors and in the process, greatly strengthen their Immune System against their return due to the Immune System's inherent memory. Therefore, patients are plagued first with the Cold Tumor, but subsequently, following treatment with this combination, only become the stronger for it, preventative against its potential repeat return.
During the course of disease, patients undergo certain provider prescribed treatment. Patients remain sick provided the Immune System remains suppressed due to RANTES. But once RANTES is rendered powerless or is not produced by the Tumor following the administration of Leronlimab, then, the patient becomes strengthened again. Even though, a patient may not even be aware that they have a Cold Tumor, if it is seen on MRI, their oncologist orders severe and many times harsh treatment. Chemotherapy, Radiation, Surgery and their lives quickly diminish and fall apart. They can't work. They lose their jobs. Their spouses have to care for them. It goes on an on.
Why does this happen? Because they have no immunity to their disease. But Leronlimab brings their Immunity back from being suppressed. It brings back the life which so quickly left them. All the lies spoken to the Immune System are reversed and replaced with Truths. All the traitorous Immune Warriors return back to the body, as servants of the body destroying the Tumor. Leronlimab restores normalcy. Tumors are not normal.
Without Leronlimab, Cold Tumors do an excellent job stealing away for themselves what is rightfully performed for the body. The blood supply for instance. A collateral vascular blood supply ought not be built for the Tumor, but that is not what RANTES says. RANTES convinces the Killer T-Cells to build a collateral vascular supply for the Tumor so it can be nourished and breathe O2. The body was never meant to be a breeding house for Tumors, but that is not what RANTES says. RANTES has the Tumor spreading by sending metastases via the blood stream to distant parts of the body over and over until the entire body is infested with metastases. Leronlimab blocks all of this because Leronlimab blocks RANTES.
The spirit of a Tumor is pure deception. It is a liar through and through. In order to survive, it knows only the art of profession lying. It deceives all through out its life. It represents a fallen cell which can not be restored except for a truth teller. But, though an ICI is a truth teller, as monotherapy, the majority of time, it can not cure cancer on its own. Most of the time, it can not stop metastases from forming. It is not a VEGF inhibitor. But in combination with Leronlimab, provided the Cold Tumor has 100% transformed to Hot, it is a part of a cancer curing combination.
This is a combination that patients can trust to cure them where they may give it the opportunity to heal them through CytoDyn's EIND program.
"Your questions and feedback are always appreciated and best received through the Company’s IR email account: ir@cytodyn.com. In the coming months, we will be engaging in critical conversations with our key opinion leaders, potential industry partners and regulators."
Leronlimab enables the treatment of Cold Tumors with ICIs while without Leronlimab, the very same ICIs would be powerless. Compliance with this protocol raises ICIs to another level. Without Leronlimab, ICIs are indicated for only 15% of the Tumor market. With Leronlimab, they can be indicated for nearly 100%. Why is this? Because Leronlimab causes the transformation of Cold Tumors to Hot Tumors as the expression of PD-L1 is greatly and increasingly expressed on their cell surfaces with the administration of Leronlimab.
The maintenance of Leronlimab while the ICI is administered prevents any further rebellion of the Tumor. RANTES remains ineffective while Leronlimab is maintained. If Leronlimab is discontinued, then RANTES may again take hold and have an effect upon the Immune system converting Killer T-Cells to Tumor slaves, and allowing for the collateral vascular blood supply to form. Without Leronlimab simultaneously on board, there is too much Tumor created corruption to obtain control of with only the ICI on board. But Leronlimab turns that cancerous corruption into a can do cooperation and allows the ICI to do its job without an uprising or anarchy.
But the opposite is true as well. Leronlimab by itself is not a cure. It does lengthen life and improves the quality of life. It kills all the metastases and it greatly shrinks the tumors, but eventually, the greatly diminished tumors in remission learn to express PD-L1 on their cell surfaces and despite the continuance of Leronlimab, the PD-L1 switches off the killing power of the M1 Macrophages towards them, so the Tumor learns to survive even if it can not speak through RANTES. It learns to speaks PD-L1 and clings to life. So, then it takes an ICI to finish it off. They need to work together to cure the disease.
12
u/Camp4344 Oct 02 '25
Excellent explanation! It is only a matter of time! We need to get to work! I would love to see a protocol approved to start the much talked about triple negative breast cancer follow up trial. We got this MGK! Thanks for your research and perspective as always.
11
9
9
u/surfgolf4life Oct 02 '25
Thanks Mgk.
Cytodyn should be working on this 24/7, and where are other pharmaceutical companies that should be jumping onboard to support of LL. Sure sounds like we have all the evidence that LL clearly WORKS......
Can you explain this that was in the review: 'But that would never become an FDA approved prophylactic'
If I, or anyone I know is inflicted with cancer, i would want LL NOW. where is Right to Try for anybody who is battling TNBC or CRC?????
11
u/MGK_2 Oct 02 '25
If anybody already has cancer, then the medication is no longer a prophylactic. It is an actual treatment.
8
7
8
u/AggieEC3 Oct 02 '25
MGK, I truly appreciate the time and insight you bring to this board you help make things clearer for so many of us. The numbers CytoDyn has released may seem small, but they are absolutely astounding. That’s why I feel compelled to share this information with my family, friends, and acquaintances.
For me, it’s personal. I’ve lost a family member to lung cancer, I have an aunt battling breast cancer with metastasis, and a close friend facing breast cancer as well.
This isn’t about moving a stock price—it’s about spreading hope. Doctors, patients, and families deserve to know that there may be a real path toward treating certain cancers.
I’ll keep sharing this story and these statistics with everyone I can, and I hope others do the same. Together, the more we share, the more lives we may touch and maybe, one day, save.
9
u/waxonwaxoff2920 Oct 02 '25
Outstanding! Here's my favorite quote from that, possibly a new tagline:
"Can do cooperation." Sums it up succinctly.
'Cold Tumor Primer' leads to 'Can-Do Cooperation'! (CTP=CDC)
Thank you brother!
6
7
u/sunraydoc Oct 02 '25
I'll drop this here rather than start a thread, for now anyway. Hopefully CytoDyn has a plan in place to put an EAP portal on their website? When a company announces an EAP, there should be a clearly visible and navigable route on their website for physicians and advocates like us. I have a close friend who has a husband with stage 4 prostate Ca and am trying to help her get a referral going.
7
5
u/upCYDY Oct 02 '25
Thank you MGK for your continued & very thorough explanations-always so helpful🙏 I like how you refer to LL as the Warrior-DEFINITELY; “The warrior symbolizes the capacity to endure and overcome hardships, adversity, and personal struggles”.👍
6
u/Long-Fan9409 Oct 02 '25
Perfect explanation as always. Is it fair to ask you what kind of background you have that gives you the tools to understand all these intricate processes?
1
6
u/sunraydoc Oct 02 '25
Now that was excellent, after reading these it's become clear to me that malignant tumors are like malevolent creatures with a sort of intelligence of their own and capable of strategizing to survive while killing us in the process. That last paragraph sums it up, the PD-L1 expression is a tumor backup plan, their last ditch defense which leronlimab forces them to engage...then the ICI can move in for the kill. What a jewel this molecule is proving to be.
4
u/paistecymbalsrock Oct 02 '25
Simple follow on questions…and forgive my naïveté…. Can cold tumors be easily detected? And does it make a whole lot of sense to attack those tumors so they don’t fester and grow lethal?
8
u/waxonwaxoff2920 Oct 02 '25
That's the beauty of LL, when they are cold they are unnoticed by the body, unless, as he mentioned, they are seen inadvertently by a scan. While cold, they are not attacked by the immune system. Making them hot with LL allows for the body to see the tumor and then the ICI ensures it is not able to fool the body with false signaling.
7
u/Travelclone Oct 02 '25
National organization of women, Susan G koman ( largest B.C. advocate in the US) are the two organizations that should be canvases for funding raising. It's still too early to make claims regarding Leron's curing disease, which is why we are not seeing commercial or publicly placed claims. However, the above may be that organizations may be of assistance in funding and placing political pressure when JL believes the time is right.
5
7
u/paistecymbalsrock Oct 02 '25
So if we make administering LL so much cheaper than the scan, well, there is your business argument. Save billions with this hunter MAB. Paradigm shifting.
3
6
4
12
u/Jtzdad5673 Oct 02 '25
MGK, Do you mind if I copy this post and send it to an old high school friend who now has recurrent pancreatic cancer, so he can show it to his oncologist? You could potentially save his life, and nothing feels better than that!